Kalaris Therapeutics Inc

NASDAQ:KLRS

Biotechnology

Healthcare
$2.30 +3.52%

+$0.16 today

Market cap
$54.75M
Beta
0.14
P/E (TTM)
-2.5
EPS (TTM)
-$1.86
52W Low $2.14High $11.88

Volume 0.07M

Average 0.08M

KLRS Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Kalaris Therapeutics IncNASDAQ: KLRS

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses grows, but more slowly than its trailing trend

Q1 FY2026 other income / expenses of $977K rose 518.4% year over year, behind the +1344.0% change in trailing-twelve-month other income / expenses. Sequentially, it rose 21.7% from the prior quarter.

Context

  • Other income / expenses increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +518.4% toward the trailing-twelve-month pace of +1344.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$977K+21.7% QoQ
Last fiscal yearDec 2025
$2.71M+177.3% YoY
LTMMar 2026
$3.53M+1344.0% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+518.4%——
1 year+177.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
2.71M USD
Year-over-year change
+177.3%

Other Income / Expenses vs competitors

How KLRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1344.0% is the highest of 9, against a peer median of -42.9%.
KLRS Competitors
Other Income / Expenses for KLRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OVIDOvid Therapeutics Inc.LTM Mar 2026$23.57M USD-26.4%+162.8%330.9%
IMAImageneBio IncLTM Mar 2026$10.53M USD+5.4%+8.8%—
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$5M USD-50.6%+65.3%—
KLRSKalaris Therapeutics IncLTM Mar 2026$3.53M USD+1344.0%——
CNTXContext Therapeutics Inc.LTM Mar 2026$3.29M USD-17.6%+87.2%—
CNTBConnect Biopharma Holdings LimitedFY2025$2.79M USD-60.4%+22.4%4360.9%
STTKShattuck Labs, Inc.LTM Mar 2026$2.79M USD-35.2%+24.9%279.0%
IFRXInflaRx N.V.LTM Mar 2026-€440.14K EUR-104.4%-1.4%1500.6%
STROSutro Biopharma, Inc.LTM Mar 2026-$38.64M USD-613.7%—38.8%
Peer median (excluding KLRS) —-42.9%+24.9%330.9%

Competitors are the stored peer set for KLRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue1.12M00013K
Gross Profit(1.12M)000(13K)
Gross Margin—————
Research & Development119.62M11.76M11.71M12.34M30.75M
Selling, General & Admin49.08M2.24M1.76M42.92M15.39M
Operating Expenses168.7M14.01M13.46M55.26M46.14M
Depreciation & Amortization1.12M00013K
EBITDA(169.84M)(15.25M)(14.01M)(58.77M)(41.98M)
EBITDA Margin—————
Operating Income(169.82M)(14.01M)(13.46M)(55.26M)(46.15M)
Operating Margin—————
Interest Income1.32M005.49M0
Interest Expense0235K687K01.44M
Other Income / Expenses(1.14M)(1.48M)(1.24M)(3.51M)2.71M
Income Before Tax(170.96M)(15.49M)(14.7M)(58.77M)(43.44M)
Pre-Tax Margin—————
Income Tax Expense1.01M0000
Net Income(171.96M)(15.49M)(14.7M)(58.77M)(43.44M)
Net Margin—————
EPS (Basic)(63.00)(50.62)(42.09)(11.73)(2.85)
EPS (Diluted)(63.00)(50.62)(42.09)(11.73)(2.85)
Weighted Avg Shares2.73M3.33M4.52M5.01M15.27M
Weighted Avg Shares (Diluted)2.73M3.33M4.52M5.01M15.27M

Kalaris Therapeutics Inc

NASDAQ:KLRS

Intrinsic Alpha fair value

Locked

Current Price

$2.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.